Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.

In a report released yesterday, Joon Lee from Truist Financial maintained a Buy rating on Argenx Se (ARGX – Research Report), with a ...

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...